The stimulation of cholinergic receptors in target cells during a critical developmental period provides signals that influence cell replication and differentiation. Accordingly, environmental agents that promote cholinergic activity evoke neurodevelopmental damage because of the inappropriate timing or intensity of stimulation. Nicotine evokes mitotic arrest in brain cells possessing high concentrations of nicotinic cholinergic receptors. In addition, the cholinergic overstimulation programs the expression of genes that evoke apoptosis and delayed cell loss. Effects of cholinesterase inhibitors exhibit many similarities to those of nicotine. Chlorpyrifos administered to developing rats in doses that do not evoke signs of overt toxicity decreased DNA synthesis and caused shortfalls in cell numbers in brain regions enriched in cholinergic innervation. In embryo cultures, chlorpyrifos also evoked apoptosis during neurulation. However, chlorpyrifos also evokes noncholinergic disruption of cell development by interfering with cell signaling via adenylyl cyclase, leading to widespread disruption that is not limited to cholinergic systems. We have tested this hypothesis in vitro with PC12 cells, which lack the enzymes necessary to produce chlorpyrifos oxon, the metabolite that inhibits cholinesterase. Chlorpyrifos inhibited DNA synthesis in undifferentiated PC12 cells, which have relatively few cholinergic receptors. Furthermore, chlorpyrifos was more effective than nicotine and its effects were not blocked by cholinergic antagonists. When cells were allowed to differentiate in the presence of chlorpyrifos, cell replication was inhibited even more profoundly and cell acquisition was arrested. At higher concentrations, chlorpyrifos also inhibited neuritic outgrowth. Thus, chlorpyrifos elicits damage by both noncholinergic and cholinergic mechanisms extending from early stages of neural cell replication through late stages of axonogenesis and terminal differentiation. Accordingly, the window of developmental vulnerability to chlorpyrifos is likely to extend from the embryonic period into postnatal life. -Environ Health Perspect 107(Suppl 1): 71-80 (1999). http.//ehpnetl.niehs.nih.gov/docs/1999/Suppl-1/71-80slotkin/abstract.html
Neurotransmitters as Trophic Factors
Nearly four decades ago, Buznikov (1, 2) demonstrated that neurotransmitters were present in high concentrations during specific phases of early development in sea urchin embryos, unrelated to their function in synaptic communication. Subse- quently, transient expression of these substances and their specific receptors has been identified during ontogeny of the mammalian nervous system, and it is now certain that transmitters play essential roles in the cellular and architectural development of the brain (3, 4) . During
Manuscript received at EHP 6 August 1998; accepted this period, receptor stimulation uniquely communicates with the genes that control cell differentiation, changing the ultimate fate of the cell ( Figure 1 ). As these changes are not typical for the mature nervous system, the ontogenetic state of the target cell is critical in determining whether the outcome of receptor stimulation is an effect on cell replication, differentiation, growth, death (apoptosis), or "learning," that is, determining the future set-point for responsiveness of the cell. At the same time, these multiple roles create a wide window of vulnerability in which exposure of the brain to neuroactive chemicals that elicit or block neurotransmitter responses can alter development. Thus, unlike classical teratology, in which the first trimester of fetal development is the most sensitive target for adverse effects of drugs or chemicals, brain development is likely to be affected by exposures ranging from the early embryonic stage through adolescence (5) .
This review will focus on disruption of brain development elicited by agents targeting cholinergic transmission. Two of the most widespread chemical assaults on the fetus are cholinergic: nicotine, a direct cholinergic agonist delivered by maternal cigarette smoking, and insecticides, which enhance cholinergic effects through inhibition of cholinesterase, the enzyme that hydrolyzes acetylcholine. A focus on cholinergic mechanisms is also appropriate given the critical role played by acetylcholine in brain maturation. Cholinergic stimulation is essential for establishment of cerebrocortical cytoarchitecture, and even transient interference with cholinergic input during development produces permanent structural and behavioral damage (6) (7) (8) . Similarly, cholinergic overstimulation at an inappropriate time leads to developmental anomalies. In the rat, the peak of cholinergic tone in the cortex ordinarily occurs during the second postnatal week (9) . Administration of cholinergic agonists before that time or dietary alterations that evoke early onset of cholinergic activity result in premature cessation of neuronal mitosis, leading to shortfalls in cell numbers and deficient synaptic activity (9) (10) (11) (12) . Accordingly, it is important to explore the mechanisms underlying the actions of cholinotoxicants and their impact on the developing brain.
Nicotine: Prototypic Cholinotoxicant
The largest toxic assault on fetal development is provided by maternal cigarette smoking, which involves approximately one-fourth of all pregnancies in the United States (13, 14) . Epidemiologic studies have established the tragic results: tens of thousands of spontaneous abortions and neonatal intensive care unit admissions annually, thousands of perinatal deaths and deaths from Sudden Infant Death Syndrome (crib death), and substantially increased incidence of learning disabilities, behavioral problems, and attention deficit/hyperactivity disorder (14) (15) (16) (17) (18) (19) (20) (24) (25) (26) abnormalities, but many of these effects are caused by vasoconstrictor effects on uteroplacental circulation, evoking episodic hypoxia (27) (28) (29) (30) . Nicotine injections produce high peak plasma levels of drug, inducing obvious ischemic episodes (blanching, cyanosis) with each dose (10, 31) . Accordingly, in the mid-1980s, we developed the first animal model of fetal nicotine exposure to make use of continuous infusions delivered by implantable osmotic minipumps (9, 26, (31) (32) (33) (34) , a delivery route that avoids hypoxia-ischemia, and that delivers a fixed dose of drug simulating the steady-state plasma levels seen in smokers or users of transdermal nicotine patches (35, 36) . Pharmacokinetic and pharmacodynamic differences dictate the use of higher overall doses in rats than in humans, so that the critical end point is matching the plasma concentrations and the corresponding pharmacologic effects (36, 37) . Thus, in rats, dose rates of 2 to 6 mg/kg/day are necessary to reproduce the nicotine plasma levels found in moderate (0.5 to 1 pack/day) to heavy (2 packs/day) smokers.
With the infusion model, we have been able to show definitive damage to developing rat brain by doses of nicotine that reproduce the plasma levels found in heavy smokers (26, (31) (32) (33) (34) . Two indices of these adverse effects are illustrated in Figure 2 . In animals exposed prenatally to nicotine, ornithine decarboxylase activity, a marker enzyme for cell damage, is elevated during the postnatal period in both early-developing (forebrain) and latedeveloping (cerebellum) brain regions even though nicotine exposure terminates at birth. During the same period, deficits in total cell number, as determined by DNA content, worsen. Subsequently, we found that genes associated with programmed cell death (apoptosis) are constitutively activated by prenatal nicotine exposure (38, 39) , with effects persisting into the period of maximal cell loss; direct morphological assessment of nicotine-exposed embryos confirmed the presence of numerous apoptotic cells (40) . Nicotineinduced apoptosis in the developing brain is in direct contrast to the observation that nicotine exerts a neuroprotective effect in the adult brain (41, 42) , induding protection from injury-induced apoptosis (43, 44) . Just as with c-fos itself (45) (46) (47) , the developmental context in which nicotine exposure occurs is likely to be critical for determining whether apoptosis is evoked or suppressed. Indeed, cholinergic agonists and antagonists can both elicit apoptosis depending on whether the context involves active or desensitized receptors (48) . In the context of extended exposure to nicotine during fetal development, persistent induction of c-fos clearly is associated with enhanced cell death (31), most likely from apoptosis (40) .
We also identified a second mechanism for cell deficits caused by nicotine exposure (10): inhibition of DNA synthesis (Figure 3) . Administration of even a single dose of nicotine to pregnant or neonatal
The same neurotransmitter may be used for multiple decisions Figure 1 . Cholinotoxicant targeting of cell development. Abbreviations: AChE, acetylcholinesterase; CPF, chlorpyrifos; Nic, nicotine. During development, neurotransmitters, through their receptors and associated signaling cascades, control the genes that influence differentiation. Depending on the context in which stimulation occurs, the same neurotransmitter can promote cell replication, can elicit a switch from replication to differentiation, can promote or arrest cell growth, can evoke apoptosis, or can program the genes that determine the future responsiveness of the cell to external stimulation. Nicotine targets nicotinic cholinergic receptors located on target cells, directly evoking changes in gene expression. Presynaptic nicotinic receptors that modulate release of other neurotransmitters produce secondary alterations of target cell development through the actions of these other transmitters on their respective receptors, signaling cascades and gene expression (39) . Chlorpyrifos through its active oxon metabolite inhibits acetylcholinesterase, preventing the breakdown of acetylcholine and thus enhancing cholinergic activity. In addition, chlorpyrifos can exhibit agonistlike properties, opening and then desensitizing nicotinic cholinergic receptor/ion channels (81) , can interact with signaling intermediates such as G-proteins and adenylyl cyclase (80, 82, 83) , or can produce oxidative damage to DNA (84, 85 (10) . Simply losing cells or preventing acquisition of the correct number of cells does not inherently account for neurobehavioral disruption by nicotine exposure; instead it is necessary to demonstrate that synaptic function is affected. Because nicotine works through cholinergic receptors, we first evaluated effects on cholinergic transmission (9, 49) . Using biochemical indices of neuronal impulse activity, we found that prenatal nicotine exposure blunted the ontogenetic rise of synaptic activity in the forebrain and produced persistent deficits in the hippocampus ( Figure 4 ). However, adverse functional effects are not limited to cholinergic neurotransmission. Nicotinic receptors also play a prominent role in the activity of catecholaminergic systems, and we found that fetal nicotine treatment had adverse effects on these synapses as well, again with the effects appearing well after termination of nicotine exposure. Catecholaminergic function showed two phases of synaptic hypoactivity, one in the immediate postpartum period and another emerging with the onset of puberty (33) , accompanied by behavioral anomalies (36, 50, 51) . In the intervening stages, even though basal activity was within normal limits, the reactivity of noradrenergic systems to acute nicotine challenge was obtunded in the prenatal nicotine group ( Figure 4 ): doses of nicotine that evoked norepinephrine release in brain regions of control animals were unable to do so in the group exposed to nicotine prenatally (52) . Thus, fetal exposure to nicotine has lasting adverse effects on synaptic performance, effects that may not emerge fully until adolescence.
We Figure 4 . Synaptic hypoactivity elicited by prenatal nicotine exposure. (A) In the forebrain, the ratio of choline uptake to choline acetyltransferase activity (a biochemical marker of impulse activity in cholinergic projections) Figure 3 . Inhibition of DNA synthesis in rat brain shows a naturally occurring peak at postnatal day 10; nicotine blunts activity before and during the developmental regions after a single dose of nicotine (10, 31, 106) . spike (9) . (B) In the hippocampus, [3H]hemicholinium-3 binding to the high-affinity choline transporter, which is Measurements of PHithymidine incorporation into DNA regulated by nerve impulse activity, shows both initial postnatal deficits and a later-emerging, permanent deficit in were made in the first 30 min after nicotine administra-the nicotine group (49) . (C) Noradrenergic hypoactivity is also elicited by prenatal nicotine exposure. tion. Susceptibility is directly related to the concentra-Norepinephrine content and turnover are suppressed in the forebrain during both the initial postnatal period, and tion of nicotinic cholinergic receptors in each region, more persistently with the onset of puberty (33 (74) . Nevertheless, recent concern has arisen over domestic application, which can lead to infant exposures well above acceptable levels (75, 76) . Animal studies indicate that immature animals are far more susceptible to acute toxicity of chlorpyrifos (77-79) despite the fact that they recover from cholinesterase inhibition more quickly than adults (78) (79) (80) . As with other organophosphate insecticides, chlorpyrifos, via its reactive metabolite, chlorpyrifos oxon, inhibits cholinesterase and prevents the breakdown of acetylcholine. An initial view of the potential impact of chlorpyrifos on signaling targets in brain development thus could resemble that of nicotine ( Figure 1) , with promotion of cholinergic signaling as the primary target. However, chlorpyrifos also exhibits direct cholinergic agonistlike properties, opening and then desensitizing nicotinic cholinergic receptor/ion channels (81); it interacts with signaling intermediates such as G-proteins and adenylyl cyclase (80, 82, 83) ; and it may produce oxidative damage to DNA (84, 85) .
If the primary effect of chlorpyrifos on the developing brain is a reflection of its general mode of toxicity as seen in mature animals, namely cholinesterase inhibition, then the net effects during development should bear a strong resemblance to those of nicotine, which also elicits cholinergic hyperstimulation. When we administered chlorpyrifos to neonatal rats (Figure 6 ), we obtained acute inhibition of DNA synthesis (77) . However, at 1 day of age, there was no regional selectivity to the effect: regions with low cholinergic innervation (cerebellum) were affected just as much as cholinergically enriched regions (brainstem, forebrain). Regional selectivity then emerged by the end of the first postnatal week, at which point cholinergic antagonists could block the effect. Thus, chlorpyrifos affects DNA synthesis by at least two different types of mechanisms, an initial, noncholinergic effect, and subsequently, actions mediated through cholinergic activity. In support of the unexpected finding of noncholinergic contributions to effects on DNA synthesis, we obtained the same inhibitory actions when minute amounts of chlorpyrifos were injected directly into the brain, bypassing hepatic activation to chlorpyrifos oxon, the metabolite that inhibits cholinesterase. The contributions of noncholinergic mechanisms to the net adverse effect on brain development are readily demonstrable. With repeated chlorpyrifos administration, we obtained persistent inhibition of DNA synthesis (86) , leading to deficits in cell number (87) and suppression of macromolecular constituents (88) . These effects were seen at chlorpyrifos exposure levels that were devoid of any overt toxicity and that reduced cholinesterase activity by only 20% (80), a degree of inhibition insufficient to produce signs of systemic toxicity.
Some of the postulated, noncholinergic effects of chlorpyrifos involve cell signaling intermediates common to multiple neuronal and hormonal inputs, especially the adenylyl cyclase transduction pathway (82, 83, 89) . Cyclic AMP is universally involved in the control of cell replication and differentiation in virtually all prokaryotic and eukaryotic cells (90) (91) (92) (93) (94) , so that perturbation of this pathway during development would be expected to have a significant impact on brain cell development. When we examined the effects of otherwise subtoxic doses of chlorpyrifos on adenylyl cyclase activity in the developing brain (80), we found profound effects on Gprotein-mediated signaling, including that operating through neurotransmitter receptors known to play neurotrophic roles in cell replication/differentiation patterns ( Figure 7) . Importantly, low doses of chlorpyrifos administered early in development, with minimal cholinesterase inhibition, had a much greater effect on adenylyl cyclase activity than larger doses given later in development, even though the latter treatment produced much greater inhibition of cholinesterase. Again Age, days Figure 7 . Effects of repeated chlorpyrifos administration on forebrain adenylyl cyclase activity (80 (100) . The effect on DNA synthesis in undifferentiated PC12 cells could not be blocked by cholinergic receptor antagonists, confirming that chlorpyrifos itself produces effect without a requirement for cholinesterase inhibition and its resultant cholinergic hyperstimulation. When PC12 cells were allowed to differentiate in the continuous presence of chlorpyrifos, the inhibition of DNA synthesis intensified and persisted throughout the period of cell development ( Figure 9 ). As a consequence, acquisition of new cells (DNA level) was severely curtailed, or at the highest concentrations, completely arrested, replicating the effects found for chlorpyrifos in vivo. In contrast to the profound effects on DNA synthesis and cell acquisition, neurite extension, as measured by the increase in membrane surface area (protein/DNA ratio), was inhibited only at high chlorpyrifos concentrations. These results confirm a targeted, primary effect of chlorpyrifos on cell replication, with other developmental abnormalities requiring higher exposure levels. Just as was found for in vivo treatments, the progression of cell differentiation increases the sensitivity to chlorpyrifos, representing emergence of the cholinergic target phenotype; at that point, both direct and cholinergically mediated effects become additive (77) , whereas only the direct effects can be expressed in the undifferentiated state.
We have also carried out in vitro studies in rat embryo cultures (67) (77, 80, 86) , leading to deficiencies in cell numbers (87) . A preliminary report on pregnant rats (103) found that a comparable degree of cholinesterase inhibition, which is well below the threshold for any observable signs of cholinergic hyperstimulation, produces peak fetal brain concentrations of the major metabolite of chlorpyrifos of approximately 0.25 pg/g, which on a molar basis, corresponds to the lowest concentration of chlorpyrifos used in our studies with embryos in vitro (67) . On a body weight basis, the doses of chlorpyrifos needed for adult or developmental toxicity in rats range up to tens to hundreds of mg/kg (78, 79, 104, 105) and certainly no lower than 2 mg/kg (77) . Mitotic arrest in vivo occurs with brain concentrations of 2 i'g/g (77) , again well within the concentration range needed for in vitro effects. The likely acute exposure level for infants after home application of chlorpyrifos is also above this range: 350 pg/kg/day for a 2-week period, for a total of 5 mg/kg (76) . Although there are clear limitations of extrapolation across species and between cultures and intact systems, in vitro evaluations nevertheless can point the way to likely mechanisms and adverse outcomes, and are likely to be within the range of relevant exposure levels in vivo.
Conclusions and Future Directions
Drugs or chemicals that target cholinergic neurotransmission probably represent the largest source of neurobehavioral teratogenesis. Nicotine exposure involves onefourth of all pregnancies in the United States, and exposure to insecticides that target cholinesterase is ubiquitous. Establishing the underlying mechanisms, and hence safety thresholds, for these compounds must represent a major focus of future work. We have shown that nicotine damages the developing brain at concentrations achieved in moderate smokers or with nicotine replacement therapies such as the transdermal patch. The sequelae of maternal smoking are already well established (14) and include high rates of miscarriage, fetal death, intrauterine growth retardation, deaths in the postnatal period, and behavioral and learning disturbances. The finding that a specific substance in tobacco (nicotine) is a major contributor to adverse outcomes provides the first definitive proof that tobacco is a direct cause of these problems, not simply a covariable with other components of the smoking life style. In the case of chlorpyrifos, our 
